Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05898776 · ClinicalTrials.gov registry record · NA

10°C vs 4°C Lung Preservation RCT

A NA study of Lung Transplant and Organ Preservation, sponsored by University Health Network, Toronto.

Active
Registry status
NA
Development phase
317
Enrollment target
17
Study locations

NCT05898776: Active NA study of Lung Transplant and Organ Preservation, sponsored by University Health Network, Toronto.

NCT05898776 is a NA study of Lung Transplant and Organ Preservation that is active but no longer recruiting, run by University Health Network, Toronto. The registered enrollment target is 317 participants, below the 1,255-participant average among 15 other Lung Transplant trials with a reported enrollment target (75% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05898776, a NA study of Lung Transplant and Organ Preservation, is active but no longer recruiting, sponsored by University Health Network, Toronto.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
317 participants
Enrollment target
17
Study locations

Study Summary

Despite lung transplantation (LTx) being the most effective treatment for end-stage lung disease, its success rate is lower than that of other solid organ transplantations. Primary graft dysfunction (PGD) is the most common post-operative complication and a major factor in early mortality and morbidity, affecting \~25% of lung transplant patients. Induced by ischemia reperfusion, PGD represents a severe and acute lung injury that occurs within the first 72 hours after transplantation, and has a significant impact on short- and long-term outcomes, and a significant increase in treatment costs. Any intervention that reduces the risk of PGD will lead to major improvements in short- and long-term transplant outcomes and health care systems. One of the main strategies to reduce the risk and severity of post-transplant PGD is to improve pre-transplant donor lung preservation methods. In current practice, lung preservation is typically performed by cold flushing the organ with a specialized preservation solution, followed by subsequent hypothermic storage on ice (\~4°C). This method continues to be used and applied across different organ systems due to its simplicity and low cost. Using this method for the preservation of donor lungs, the current maximum accepted preservation times have been limited to approximately 6-8h. While the goal of hypothermic storage is to sustain cellular viability during ischemic time through reduced cellular metabolism, lower organ temperature has also been shown to progressively favor mitochondrial dysfunction. Therefore, the ideal temperature for donor organ preservation remains to be defined and should maintain a balance between avoidance of mitochondrial dysfunction and prevention of cellular exhaustion. In addition to that, safe and longer preservation times can lead to multiple advantages such as moving overnight transplants to daytime, more flexibility to transplant logistics, more time for proper donor to recipient matching etc. Build

Primary Outcome

PGD is graded on a scale of 0 to 3 based on ISHLT guidelines, where PGD Grade 3 indicates severe primary graft dysfunction.

Interventions

  • DEVICE Lung transplantation after 10°C donor lung preservation
  • DEVICE Lung transplantation after standard ice cooler donor lung preservation

Study Locations (17)

Other

  • Medical University of Vienna - Vienna
  • University Hospitals Leuven - Leuven
  • The Saint Joseph Hospital Foundation (Hôpital Marie Lannelongue) - Paris
  • Hospital Universitario 12 de Octubre - Madrid
  • Hospital Universitario Puerta de Hierro-Majadahonda - Madrid
  • Centre Hospitalier Universitaire Vaudois (CHUV) - Lausanne
  • University Hospital Zurich - Zurich

Arizona

  • Dignity Health (St. Joseph's Hospital and Medical Center) - Phoenix

California

  • University of California San Francisco - San Francisco

Florida

  • University of Miami - Coral Gables

Michigan

  • Corewell Health Research Institute - Grand Rapids

Minnesota

  • Mayo Clinic - Rochester

Tennessee

  • Vanderbilt University Medical Center - Nashville

Texas

  • University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 317 participants
Start Date 2023-06-09
Est. Completion 2026-11-22
Phase NA
University Health Network, Toronto

23 total trials

What the registry record for NCT05898776 still lists

NCT05898776 is an interventional study that assigns participants to a tested intervention. The registered 317 participants enrollment target is mid-sized for trials with a published cap, below the 1,255-participant average among 15 other Lung Transplant trials with a reported enrollment target (75% lower).

The record links to 2 conditions, with Lung Transplant appearing as the primary indexed condition, and to 2 interventions - of which Lung transplantation after 10°C donor lung preservation is the first listed.

NCT05898776 lists 17 locations in 11 states (Other, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT05898776 about?

NCT05898776 is a clinical study titled "10°C vs 4°C Lung Preservation RCT". Despite lung transplantation (LTx) being the most effective treatment for end-stage lung disease, its success rate is lower than that of other solid organ transplantations. Primary graft dysfunction (PGD) is the most common post-operative complication and a major factor in early mortality and morbid...

What is the current status of trial NCT05898776?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 317 participants. The study started on 2023-06-09. Estimated completion is 2026-11-22.

What conditions does trial NCT05898776 study?

This clinical trial studies the following conditions: Lung Transplant, Organ Preservation.

What interventions are being tested in trial NCT05898776?

The interventions under investigation include: Lung transplantation after 10°C donor lung preservation (DEVICE), Lung transplantation after standard ice cooler donor lung preservation (DEVICE).

Who is sponsoring clinical trial NCT05898776?

This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05898776 being conducted?

This trial has 17 study locations across Arizona, California, Florida, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05898776's enrollment target sits among peer trials

317 4th of 15 higher than 12 of 15 other Lung Transplant trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04594642 · 317 participants · Phase 1

    A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

  • NCT04977453 · 317 participants · Phase 1

    GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

  • NCT05137054 · 317 participants · Phase 1

    A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  • NCT05382754 · 317 participants · NA

    Home Apnea Testing in CHildren Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05898776, the US trial registry maintained by the National Library of Medicine. NCT05898776 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.